TNF-Alpha is a primary mediator in many chronic inflammatory conditions such as rheumatoid arthritis, chronic inflammatory bowel disease, psoriasis etc. Recognition of its role in bringing about inflammation has led to a new, targeted approach towards treating such conditions. Now, specific TNF-Alpha inhibitors are used to counter act the effects of this mediator of inflammation and reverse the condition. Such drugs represent a subgroup called biologics (technologically produced drugs of biologic origin). Most of these drugs have two active ingredients: adalimumab and infliximab.
During the course of treatment with these drugs, the active ingredient is continuously increased initially until the point where an optimal status and significant improvement in the symptoms is achieved. Thereafter an increase in the active ingredient will only lead to side effects. To determine the proper doses, individual specific pharmacokinetics and dynamics are applied and the drugs levels are constantly monitored from the start of the therapy.
A common problem that occurs with the use of these drugs is the formation of anti-drug antibodies. Hence, ADA estimations are necessary for making any therapeutic adjustments in cases of drug resistance.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.
|568||ELISA||MabTrack level adalimumab|
|569||ELISA||MabTrack anti-drug antibody adalimumab|
|570||ELISA||MabTrack level infliximab|
|571||ELISA||MabTrack anti-drug antibody infliximab|
2023 EUROIMMUN US